CYP20A1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P09575(CYP20A1 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P09575(CYP20A1 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The CYP20A1 antibody targets the cytochrome P450 family 20 subfamily A member 1 (CYP20A1), a poorly characterized enzyme within the cytochrome P450 superfamily. Unlike many CYP enzymes involved in drug metabolism or xenobiotic detoxification, CYP20A1’s physiological substrates and precise biological functions remain unclear. It is expressed in various tissues, including the brain, liver, and kidneys, suggesting potential roles in endogenous metabolic pathways. Structural studies indicate it may possess atypical catalytic features compared to other CYPs, possibly linked to cholesterol or neurosteroid metabolism.

CYP20A1 antibodies are primarily used in research to study its expression patterns, subcellular localization (notably endoplasmic reticulum association), and regulatory mechanisms. Emerging evidence implicates CYP20A1 in neurological disorders, such as Parkinson’s disease, and cancer progression, though mechanistic insights are limited. Some studies report elevated CYP20A1 levels in gliomas or colorectal cancers, hinting at its potential as a diagnostic or prognostic marker. However, inconsistent expression data across studies underscore the need for further validation.

Commercial CYP20A1 antibodies are typically developed against specific epitopes, often validated via Western blotting, immunohistochemistry, or immunofluorescence. Researchers must verify antibody specificity due to homology with other CYPs and the protein’s low abundance. Current investigations focus on clarifying its enzymatic activity, interaction networks, and disease relevance, positioning CYP20A1 as a molecule of growing interest in metabolic and oncological research.